Clinical Trials Browser

INDUSTRY × Bevacizumab × Sarcoma × Clear all

Advanced Solid Tumors

NCT04553692 2025-03-28

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

GastrointestinalLymphoidOther hematologic neoplasmSarcoma

Chondrosarcoma, Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myeloid, Acute

NCT01903330 2025-03-05

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

Phase 2 Active not recruiting

84 enrolled

CNSSarcoma

Glioblastoma, Gliosarcoma

NCT05824975 2024-11-25

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Phase 1/2 Recruiting

358 enrolled

DermatologicGastrointestinalGenitourinarySarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT04999761 2024-09-25

AB122 Platform Study

Phase 1 Recruiting

917 enrolled

GastrointestinalHead & NeckSarcomaThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasm Metastasis, Stomach Neoplasms, Colorectal Neoplasms, Sarcoma, Alveolar Soft Part

NCT02052648 2024-03-27

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

Phase 1/2 Completed

160 enrolled 21 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT04861948 2022-10-04

IBI188 Combination Therapy in Solid Tumors

Phase 1 Terminated

9 enrolled

SarcomaThoracic

Adenocarcinoma of Lung, Osteosarcoma

NCT02330562 2022-06-08

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Phase 1/2 Completed

121 enrolled 27 charts

CNSSarcoma

Brain Neoplasms, Glioblastoma, Glioma, Gliosarcoma

NCT01327612 2021-02-21

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

Phase 2 Completed

12 enrolled 21 charts

EndocrineGastrointestinalLymphoidSarcomaThoracic

Carcinoid Tumor, Carcinoma, Non-Small-Cell Lung, Lymphoma, Neoplasm Metastasis, Sarcoma, Colorectal Neoplasms

NCT01498328 2020-02-17

ReACT

Phase 2 Completed

127 enrolled

CNSSarcoma

Brain Neoplasms, Glioblastoma, Neoplasms, Recurrence, Gliosarcoma

NCT00643565 2019-10-22

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

Phase 2 Completed

154 enrolled 19 charts

Sarcoma

NCT02574663 2019-10-02

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Phase 1 Completed

66 enrolled

GastrointestinalSarcoma

Esophageal Neoplasms, Pancreatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Gastrointestinal Stromal Tumors

Clinical Trials

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers

ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme

A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

AB122 Platform Study

Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors

IBI188 Combination Therapy in Solid Tumors

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)

ReACT

A Study of Avastin (Bevacizumab) in Combination With Standard Chemotherapy in Children and Adolescents With Sarcoma.

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors